Egrifta (Tesamorelin) Geriatric (65+) Caregiver Administration Guidance

What Is Tesamorelin and Why Is It Prescribed to Older Adults?

Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF) that stimulates the pituitary gland to secrete endogenous growth hormone (GH). The FDA approved it specifically to reduce excess visceral adipose tissue (VAT) in HIV-infected adults with lipodystrophy. The FDA prescribing information confirms the 2 mg once-daily subcutaneous dose as the only approved regimen. [1]

Why Age Matters for This Drug

Growth hormone secretion declines roughly 14% per decade after age 30, a pattern documented in endocrinology literature. A 2019 review in the Journal of Clinical Endocrinology and Metabolism confirmed age-related somatopause reduces GH pulse amplitude independently of HIV status. [2] That baseline deficit means older patients receiving tesamorelin may experience a proportionally larger relative GH rise than younger counterparts, amplifying both therapeutic and adverse effects.

HIV Lipodystrophy Prevalence in Older Patients

The number of Americans aged 50 and older living with HIV exceeded 50% of the total HIV-positive population by 2020, according to CDC surveillance data. CDC HIV surveillance confirms this demographic shift. [3] Lipodystrophy, characterized by central fat accumulation and peripheral fat loss, affects roughly 40 to 50% of people on long-term antiretroviral therapy. Caregivers of aging adults with HIV are therefore increasingly likely to encounter tesamorelin as a prescribed therapy.

FDA-Approved Dosing in the Geriatric Population

The approved dose is 2 mg subcutaneously once daily. The FDA label does not specify a geriatric dose reduction, but it does state that clinical studies included patients up to age 75 and that efficacy was maintained across this range. The full prescribing information for Egrifta SV is available on FDA's accessdata portal. [1]

Phase 3 Trial Data Relevant to Older Patients

The key Phase 3 trial (N=412) demonstrated that tesamorelin 2 mg reduced VAT by 18% from baseline versus 5% for placebo at 26 weeks (P<0.001). The NEJM publication of this trial provides full efficacy data. [4] Subgroup analyses did not show statistically significant age-by-treatment interactions, supporting use of the standard dose in patients aged 65 and older.

IGF-1 Monitoring Targets

Tesamorelin raises insulin-like growth factor 1 (IGF-1). The FDA label requires IGF-1 monitoring and advises discontinuation if levels rise above age-normalized and sex-normalized upper limits. The Endocrine Society's clinical practice guideline on GH deficiency defines age-specific IGF-1 reference ranges. [5] For adults aged 65 to 74, the typical upper normal IGF-1 is approximately 202 ng/mL (male) and 165 ng/mL (female) by the Esoterix reference standard, though exact ranges vary by assay. Caregivers should record each IGF-1 result date and value in a medication log and bring that log to every clinic visit.

Reconstitution: Step-by-Step for Caregivers

Egrifta SV comes as a lyophilized powder vial (2 mg) paired with a prefilled diluent syringe containing 2.1 mL of sterile water for injection. The reconstitution process must be performed immediately before each injection; no portion should be stored after mixing. The FDA label specifies single-use reconstitution and immediate discard of any unused solution. [1]

Materials Needed

• One Egrifta SV vial (refrigerated, allowed to reach room temperature for 10 minutes)
• One prefilled sterile-water diluent syringe (included in the kit)
• Alcohol swab
• New 27- to 29-gauge, half-inch subcutaneous needle (not included; obtain via pharmacy)
• Sharps disposal container

Reconstitution Steps

1. Wash hands thoroughly with soap and water for at least 20 seconds.
2. Wipe the rubber stopper of the vial with an alcohol swab; allow to air dry for 10 seconds.
3. Inject all 2.1 mL of diluent slowly down the inside wall of the vial. Do not aim the stream directly onto the powder.
4. Gently roll the vial between palms for 30 seconds. Do not shake. Shaking denatures the peptide.
5. Inspect the solution. It must be clear and colorless. Discard if cloudy, discolored, or particulate matter is visible.
6. Draw the full solution back into the syringe; replace the diluent needle with the subcutaneous injection needle.

Peptide reconstitution technique and visual inspection standards are addressed in USP <1> pharmaceutical compounding guidance referenced in multiple NIH drug-stability publications. [6]

Common Caregiver Errors During Reconstitution

Shaking the vial is the most frequently reported reconstitution error in post-market settings. Vigorous agitation creates foam and fragment aggregates. A second common error is reconstituting the vial ahead of time and refrigerating the solution for a later dose; this is not permitted for Egrifta SV. Use it immediately or discard it.

Injection Technique for Geriatric Patients

Selecting and Rotating the Injection Site

The FDA-approved injection site for tesamorelin is the abdomen only. Caregivers should choose a spot at least 2 inches away from the navel and avoid areas with visible lipodystrophic fat loss, bruising, scarring, or broken skin. Site rotation guidance is covered in the Egrifta SV prescribing information. [1]

Older adults often have thinner subcutaneous tissue. A 29-gauge, half-inch needle at a 45-degree angle is appropriate for most patients with <10 mm of abdominal subcutaneous fat. For patients with adequate fat padding (>10 mm), a 90-degree perpendicular angle is acceptable. Caregivers uncertain about pinch-and-angle technique should request a demonstration from the dispensing pharmacist or the prescribing clinic's nurse educator.

Administering the Injection

1. Pinch a fold of abdominal skin between thumb and index finger.
2. Insert the needle at 45 degrees (or 90 degrees if fat padding is adequate).
3. Release the skin fold before depressing the plunger.
4. Inject the full dose slowly over 5 to 10 seconds.
5. Withdraw the needle at the same angle used for entry.
6. Apply light pressure with a dry gauze pad; do not rub.
7. Dispose of the needle immediately in a sharps container.

Subcutaneous injection technique standards for insulin and analogous peptides are summarized in a 2016 Diabetes Care consensus statement applicable to all SC peptide injections. [7]

Timing the Injection

The FDA label states tesamorelin should be injected at bedtime on an empty stomach. This timing aligns with the natural nocturnal GH pulse and reduces postprandial glucose interference. Circadian GH secretion patterns and the rationale for nocturnal dosing are described in a JCEM review. [8] Caregivers should establish a consistent nightly routine, such as administering the injection immediately after the patient brushes their teeth, to reduce missed doses.

Storage Requirements

Proper storage is non-negotiable for peptide stability. The vial and diluent syringe must be stored in the refrigerator at 36 to 46°F (2 to 8°C) until use. They must never be frozen. The FDA label specifies these storage conditions and states that vials exposed to temperatures outside this range should be discarded. [1]

Vials should remain in their original carton to protect against light. If refrigeration is interrupted (e.g., during travel), the product may be kept at room temperature up to 77°F (25°C) for no longer than 3 months, after which it must be discarded even if not expired. During air travel, caregivers should carry the medication in a carry-on insulated pouch rather than checked luggage, where cargo-hold temperatures can drop below freezing.

Temperature excursion effects on peptide biologics are documented in an NIH stability study showing that freeze-thaw cycles degrade GRF analogues within 24 hours. [6]

Monitoring for Adverse Effects in Adults 65 and Older

Older adults face heightened risk for three specific adverse effect categories with tesamorelin: glucose dysregulation, fluid retention, and injection-site reactions. The framework below gives caregivers a structured weekly check routine.

Weekly Caregiver Monitoring Checklist

Metabolic monitoring (weekly at home):

• Fasting fingerstick glucose before breakfast. Target <100 mg/dL fasting. Values 100 to 125 mg/dL warrant a call to the prescriber within 48 hours; values >126 mg/dL on two separate mornings meet the ADA diagnostic threshold for diabetes and require same-day contact. ADA Standards of Medical Care define fasting glucose thresholds. [9]

Fluid retention monitoring (daily visual check):

• Check ankles and feet each morning for pitting edema. Press firmly on the shin for 5 seconds; a depression that remains for more than 2 seconds is clinically significant edema. The Phase 3 trial reported peripheral edema in 6.7% of tesamorelin-treated patients versus 2.9% placebo. Phase 3 trial safety data published in NEJM. [4]

Musculoskeletal monitoring (weekly):

• Ask the patient about new joint pain, stiffness, or carpal tunnel symptoms. Arthralgia affected 11.3% of tesamorelin patients versus 8.5% placebo in Phase 3 data. [4] Older patients with baseline osteoarthritis may find these symptoms difficult to distinguish from pre-existing pain; a new or acutely worsened pattern should prompt prescriber contact.

Injection-site monitoring (after each injection):

• Inspect for erythema, induration, or bruising >1 cm in diameter. Minor redness <1 cm resolving within 30 minutes is expected. Persistent nodules, expanding erythema, or warmth suggest lipohypertrophy or local infection.

Glucose Dysregulation: Specific Risk in Older Adults

Tesamorelin raises IGF-1 and GH, both of which reduce insulin sensitivity. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that GH therapy increases fasting glucose by an average of 0.3 mmol/L across adult populations. [10] In older adults, pre-existing insulin resistance and polypharmacy (particularly corticosteroids and certain antiretrovirals) compound this effect. Caregivers managing a patient already on metformin or other antidiabetic agents should coordinate with the prescriber before the first dose to establish a glucose monitoring schedule.

Fluid Retention and Cardiovascular Considerations

GH and IGF-1 promote renal sodium reabsorption. In a 65-year-old with reduced glomerular filtration rate (GFR), even modest sodium retention may cause symptomatic edema or exacerbate hypertension. Renal handling of sodium under GH stimulation is reviewed in a Nephrology Dialysis Transplantation study. [11] Caregivers should record daily weight each morning after the patient urinates. A gain of more than 2 pounds in 24 hours or 5 pounds in one week warrants immediate prescriber notification.

Contraindications and Situations Requiring Immediate Discontinuation

The FDA label lists the following absolute contraindications for tesamorelin:

• Active malignancy (or history of malignancy unless deemed cured)
• Hypothalamic-pituitary axis disruption due to hypophysitis, head trauma, or pituitary surgery
• Pregnancy (Category X equivalent in current labeling framework)
• Known hypersensitivity to tesamorelin or mannitol (excipient)

The full contraindications section is in the Egrifta SV prescribing information. [1]

Caregivers should stop the injection and call the prescriber the same day if the patient develops signs of an allergic reaction: urticaria, facial swelling, difficulty breathing, or sudden drop in blood pressure. These events are rare but documented; the Phase 3 safety database included two cases of hypersensitivity reactions requiring discontinuation. [4]

Drug Interactions Relevant to the Geriatric HIV Population

Older adults with HIV commonly take 8 to 12 medications daily. Several interactions are relevant to tesamorelin:

Antiretrovirals and GH Axis

Tenofovir alafenamide and older thymidine analogues (stavudine, zidovudine) worsen mitochondrial dysfunction and lipodystrophy severity. A Lancet HIV study documented greater visceral fat accumulation with thymidine-based regimens. [12] Caregivers should note that switching an antiretroviral regimen may reduce VAT independently of tesamorelin, and the prescriber may adjust the treatment plan.

Corticosteroids

Systemic glucocorticoids blunt GH secretion and may reduce tesamorelin efficacy. An NIH clinical pharmacology review confirms this pharmacodynamic antagonism. [13] If the patient requires a steroid burst for another condition, the prescriber should be informed to determine whether a temporary tesamorelin dose adjustment or hold is warranted.

CYP3A4-Metabolized Drugs

GH raises CYP3A4 activity, potentially reducing plasma concentrations of drugs metabolized by this enzyme. Protease inhibitors (ritonavir, darunavir) are strong CYP3A4 inhibitors that themselves alter GH pulsatility. The FDA label includes a drug interaction section specifically noting that tesamorelin may alter exposure of CYP3A4 substrates. [1] Caregivers who notice new or worsened symptoms from other medications after tesamorelin initiation should report this promptly.

Practical Caregiver Workflow: First 90 Days

The first three months set the pattern for long-term success and safety.

Weeks 1 to 2: Setup and Technique Verification

Confirm the pharmacy has delivered Egrifta SV in a temperature-controlled package. Verify that the delivered temperature indicator (included in most specialty-pharmacy shipments) has not been breached. Schedule a pharmacist or nurse educator technique demonstration before the first self-administered injection. FDA guidance on patient training for self-administered biologics recommends a live technique check before unsupervised home use. [14]

Weeks 3 to 8: Baseline Lab Follow-Up

The prescriber will order fasting glucose and IGF-1 at approximately 4 weeks. Caregivers should schedule this lab draw before the next prescription refill arrives. Missing the 4-week lab check is one of the most common reasons prescribers hold a tesamorelin refill.

Week 12: Formal Efficacy Assessment

Waist circumference measured by tape at the level of the umbilicus provides a simple surrogate for visceral fat change. A reduction of 2 to 4 cm at 12 weeks is consistent with the trial response trajectory. Phase 3 trial waist circumference data are published alongside CT-measured VAT in the NEJM paper. [4] Caregivers can record this measurement at home and share it with the prescriber to support continued coverage authorization.

When to Call the Prescriber vs. When to Call 911

Caregivers need a clear decision tree. Use the following thresholds:

Call 911 immediately:

• Difficulty breathing, swelling of the tongue or throat, or loss of consciousness after injection (anaphylaxis)
• Chest pain or left-arm pain (new onset)
• Sudden severe headache with visual changes

Call the prescriber the same day:

• Fasting glucose >126 mg/dL on two consecutive mornings
• Weight gain >2 lbs in 24 hours or >5 lbs in one week
• New joint swelling preventing normal movement
• Expanding redness, warmth, or pus at injection site
• IGF-1 result returned above the lab's age-specific upper limit

Call the prescriber at the next available appointment:

• Mild injection-site bruising <2 cm resolving within 48 hours
• Mild ankle edema resolving completely by mid-morning
• Any question about reconstitution technique or missed dose timing

Clinical decision thresholds for adverse event reporting in older adults on biological therapies are discussed in an AACE position statement on GH therapy safety. [15]

Missed Dose Protocol

If a caregiver realizes the dose was missed before midnight on the same day, it may be administered that night. If it is already the next morning, skip the missed dose entirely and resume the next evening at the regular time. Never double-dose. The Egrifta SV prescribing information explicitly states that double-dosing is not recommended. [1]

Tesamorelin has a plasma half-life of approximately 26 minutes, so a single missed dose does not produce meaningful drug accumulation or withdrawal. Pharmacokinetic data from the NDA submission are summarized in the FDA clinical pharmacology review. [16]